Literature DB >> 23389488

Disease management programmes in Germany: a fundamental fault.

Stefan Felder1.   

Abstract

In 2001 Germany introduced disease management programmes (DMPs) in order to give sick funds an incentive to improve the treatment of the chronically ill. By 1 March 2005, a total of 3275 programmes had been approved, 2760 for diabetes, 390 for breast cancer and 125 for coronary heart disease, covering roughly 1 million patients. German DMPs show a major fault regarding financial incentives. Sick funds increase their transfers from the risk adjustment scheme when their clients enroll in DMPs. Since this money is a lump sum, sick funds do not necessarily foster treatment of the chronically ill. Similarly, reimbursement of physicians is also not well targeted to the needs of DMPs. Preliminary evidence points to poor performance of German DMPs.

Entities:  

Mesh:

Year:  2006        PMID: 23389488     DOI: 10.2165/00019053-200624002-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  4 in total

1.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

2.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

3.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

Review 4.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

  4 in total
  2 in total

1.  Transatlantic convergence with respect to the fourth hurdle?

Authors:  Joshua Cohen
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

2.  The disease management program for type 2 diabetes in Germany enhances process quality of diabetes care - a follow-up survey of patient's experiences.

Authors:  Ingmar Schäfer; Claudia Küver; Benjamin Gedrose; Falk Hoffmann; Barbara Russ-Thiel; Hans-Peter Brose; Hendrik van den Bussche; Hanna Kaduszkiewicz
Journal:  BMC Health Serv Res       Date:  2010-03-03       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.